EP1608661A2 - Process for the preparaton of 7-(p-hydroxyphenylglycylamido)cephem compounds - Google Patents
Process for the preparaton of 7-(p-hydroxyphenylglycylamido)cephem compoundsInfo
- Publication number
- EP1608661A2 EP1608661A2 EP04722335A EP04722335A EP1608661A2 EP 1608661 A2 EP1608661 A2 EP 1608661A2 EP 04722335 A EP04722335 A EP 04722335A EP 04722335 A EP04722335 A EP 04722335A EP 1608661 A2 EP1608661 A2 EP 1608661A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- alkyl
- group
- methyl
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
- C07D501/06—Acylation of 7-aminocephalosporanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/36—Methylene radicals, substituted by sulfur atoms
Definitions
- the field of the invention relates to pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.
- the invention also relates to processes for the preparation of pure 7- amino (p-hydroxyphenylglycyl) cephem compounds and pharmaceutical compositions that include the pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.
- 7- amino (p-hydroxyphenylglycyl) cephem compounds such as cefprozil, cefadroxil and cefatrizine are generally prepared by reacting a cephem derivative with a reactive derivative, such as a reactive ester; a reactive amide; and a mixed-acidic anhydride of 4-hydroxyphenylglycine.
- a reactive derivative such as a reactive ester; a reactive amide; and a mixed-acidic anhydride of 4-hydroxyphenylglycine.
- British Patent GB 1,240,687 discloses a process involving reacting N-protected 4- hydroxyplienylglycine with ethyl chloroformate to obtain a carbonate derivative which is acylated with a cephem compound.
- this method gives a product of low purity.
- a major impurity formed in such a process has the structure of Formula A,
- R is a group commonly used at the 3-position in cephalosporins, for example, methyl, 1-propenyl and l,2,3-triazol-5-yl tbiornethyl.
- the present invention provides a process which results in pure 7- amino (p- hydroxyphenylglycyl) cephem compounds.
- the process of the present invention avoids purification by tedious and cumbersome processes.
- the process of the present invention reduces the impurity content of the final product, eliminates the costly and time- consuming purification steps.
- R is a group commonly used at the 3-position in cephalosporins and may include C 1 6 alkyl, C 2 6 alkenyl, C 2 _ 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . h particular, it may include methyl, 1- propenyl and l,2,3-triazol-5-yl thiomethyl.
- compositions and dosage forms containing a therapeutically effective amount of the cephem compounds of Formula I and which may also contain pharmaceutically acceptable carriers, excipients or diluents which are useful for the treatment of bacterial infections.
- a method of treating bacterial infections comprising administering to a mammal in need thereof, a therapeutically effective amount of cephem compounds of Formula I as described above.
- R is a group commonly used at the 3 -position in cephalosporins and includes C l g alkyl, C 2 6 alkenyl, C 2 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 _ 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . hi particular, it includes methyl, 1- propenyl and l,2,3-triazol-5-yl tl iomethyl.
- the process comprising:
- R' is C 1-4 alkyl and M + is an alkali metal cation
- R is C 1 6 alkyl, C,_ 6 alkenyl, C 2 _ 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl,
- the preparation of the mixed anhydride is carried out in the presence of a small amount of an acid to minimize the formation of impurity of Formula B, in the step ii) reaction,
- R is a group commonly used at the 3-position in cephalosporins, and includes C. 6 alkyl, C 2 6 alkenyl, C 2 6 alkynyl, C 2 6 alkadienyl, cyclic C 3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl.
- the process is useful for the preparation of a wide variety of 7- amino(p- hydroxyphenylglycyl) -cephalosporins, for example, cefatrizine, cefadroxil, or cefprozil, in good yield and purity.
- Examples of Dane salts of Formula III include sodium or potassium D-N-(l- methoxycarbonylpropen-2-yl)amino-p-hydroxyphenyl- acetate, and sodium or potassium D-N-(l-ethoxycarbonyl- propen-2-yl)-amino-p-hydroxyphenylacetate.
- Examples of alkyl chloro formates include ethyl chloroformate and methyl chloroformate.
- Examples of amines present as a catalyst for mixed carboxylic acid anhydride formation include N-methyl morpholine, N,N-dimethyl benzyl amine, pyridine, picoline, and lutidine.
- the mixed anhydride may be prepared in one or more solvents, including, for example, halogenated hydrocarbon, ketone, ester, ether, nitrile, aromatic hydrocarbon, amide and mixtures thereof.
- chlorinated hydrocarbons include dichoromethane and dichloroethylene;
- ketones include acetone and methyl isobutyl ketone;
- ester include ethyl acetate and isopropylacetate;
- Examples of ether include tetrahydrofuran and dioxane; a nitrile includes acetonitrile;
- aromatic hydrocarbon include toluene.
- a suitable co-solvent may be used with a solvent, for example amide.
- a suitable amide includes one or more of formamide, acetamide, N,N- dimethyl formamide, N-methylacetamide, N,N-dimethylacetamide and N- methylpyrrolidone. Mixtures of all of these solvents are also contemplated.
- the formation of the mixed carboxylic acid anhydride may be carried out at temperatures, from about -80°C to about 50°C, or from about -50°C to about 5°C.
- step i) is generally obtained as a solution or a suspension of the mixed carboxylic acid anhydride, and can be further used as such. If desired, this anhydride may be maintained at from about -60°C to about -20°C.
- the 7-amino-ceph-3-em-4-carboxylic acid of Formula II maybe silylated with silylation agents in a solvent inert under the reaction conditions.
- silylation agents include mono- or bissilylated amides, such as N,0-bis-(trimethylsilyl)acetamide (BSA), N-methyl-N-trimethylsilyl-acetamide (MSA); silylated ureas, such as N,N'-bis- (trimethylsilyl)-urea (BSU); or silazanes, such as 1 1 3,3,3- hexamethyldisilazane (HMDS), in combination with a halosilane such as trimethylchlorsilane, dimethyldichlorosilane, or an amine, such as triethylamine, tert.octylamine.
- a halosilane such as trimethylchlorsilane, dimethyldichlorosilane, or an amine, such
- the solvents used for mixed anhydride preparation above may be used for silylation of the 7-amino-ceph-3-em-4-carboxylic acid, and also for the step ii) reaction.
- the reaction temperatures for the step ii) may be from about -60°C to room temperature or from about -40 ° C to about -10°C.
- the reaction mixture of the step ii) may be worked up in a conventional manner.
- the substituted vinyl group may be split by hydrolysis in aqueous acid.
- the final product may be isolated in a conventional manner, for example by adjusting the pH of the reaction mixture.
- the product of Formula I can be obtained in a very high purity, for example above 98%.
- the 7-amino-ceph-3-em-4-carboxylic acid of Formula II may be prepared in accordance with any of the known methods (see U.S. Patent Nos. 3,867,380; 3 489,752 and 4,520,022).
- the Dane salt of Formula III may be obtained from commercial sources or prepared by methods well known in the art.
- compounds of Formula I having less than 0.5% by weight of the impurity of Formula B can be obtained.
- compounds of Formula I having less than 0.1% by weight of the impurity of Formula B, or less than 0.05% can be obtained.
- the resulting cephem compounds of Formula I may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. hi these cases, the medicaments can be prepared by conventional methods with conventional pharmaceutical excipients.
- compositions include dosage forms suitable for oral and parenteral (including subcutaneous, intramuscular, and ophthalmic) administration.
- the oral dosage forms may include solid dosage forms, like powder, tablets, capsules, as well as liquid suspensions.
- Parenteral dosage forms may include intravenous infusions, sterile solutions for intramuscular, subcutaneous or intravenous administration, dry powders to be reconstituted with sterile water for parenteral administration, and the like.
- the suspension of silylated 7-APCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes.
- a mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C.
- the aqueous layer was diluted with dimethylformamide(700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution.
- the mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered.
- the solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 98g of cefprozil as dimethyl formamide (1.5 mole) solvate.
- the suspension of silylated 7-ADCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes.
- a mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C.
- the aqueous layer was diluted with dimethylformamide (700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution.
- the mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered.
- the solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 105g of cefadroxil as dimethyl formamide (1.5 mole) solvate.
- cefadroxil dimethyl formamide solvate was converted to white crystalline solid cefadroxil monohydrate by the procedure reported in U.S. Patent No. 4,504,657.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
Abstract
The invention relates to pure 7- amino (p-hydroxyphenylglycyl) cephem compounds. The invention also relates to processes for the preparation of pure 7- amino (p-hydroxyphenylglycyl) cephem compounds and pharmaceutical compositions that include the pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.
Description
PROCESS FOR THE PREPARATION OF 7-AMINO (p- HYDROXYPHENYLGLYCYL) CEPHEM COMPOUNDS
Field of the Invention
The field of the invention relates to pure 7- amino (p-hydroxyphenylglycyl) cephem compounds. The invention also relates to processes for the preparation of pure 7- amino (p-hydroxyphenylglycyl) cephem compounds and pharmaceutical compositions that include the pure 7- amino (p-hydroxyphenylglycyl) cephem compounds.
Background of the Invention
7- amino (p-hydroxyphenylglycyl) cephem compounds such as cefprozil, cefadroxil and cefatrizine are generally prepared by reacting a cephem derivative with a reactive derivative, such as a reactive ester; a reactive amide; and a mixed-acidic anhydride of 4-hydroxyphenylglycine.
British Patent GB 1,240,687 discloses a process involving reacting N-protected 4- hydroxyplienylglycine with ethyl chloroformate to obtain a carbonate derivative which is acylated with a cephem compound. However, this method gives a product of low purity. A major impurity formed in such a process has the structure of Formula A,
FORMULA A
wherein R is a group commonly used at the 3-position in cephalosporins, for example, methyl, 1-propenyl and l,2,3-triazol-5-yl tbiornethyl.
It was observed that this impurity is formed by reaction of ethyl chloroformate with the phenolic hydroxyl group under basic reaction conditions employed.
Thus, the present invention provides a process which results in pure 7- amino (p- hydroxyphenylglycyl) cephem compounds. The process of the present invention avoids
purification by tedious and cumbersome processes. The process of the present invention reduces the impurity content of the final product, eliminates the costly and time- consuming purification steps.
Summary of the Invention
In one general aspect there are provided pure cephem compounds of Formula I,
FORMULA I
wherein R is a group commonly used at the 3-position in cephalosporins and may include C1 6 alkyl, C2 6 alkenyl, C2_6 alkynyl, C2 6 alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . h particular, it may include methyl, 1- propenyl and l,2,3-triazol-5-yl thiomethyl.
i another general aspect there is provided a process for the preparation of cephem compounds of Formula I.
In another aspect there is provided a pharmaceutical composition and dosage forms containing a therapeutically effective amount of the cephem compounds of Formula I and which may also contain pharmaceutically acceptable carriers, excipients or diluents which are useful for the treatment of bacterial infections.
In another aspect there is provided a method of treating bacterial infections comprising administering to a mammal in need thereof, a therapeutically effective amount of cephem compounds of Formula I as described above.
The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.
Detailed Description of the Invention
The inventors have developed a process for the preparation of certain cephem compounds of Formula I,
FORMULA I
wherein R is a group commonly used at the 3 -position in cephalosporins and includes Cl g alkyl, C2 6 alkenyl, C2 6 alkynyl, C2 6 alkadienyl, cyclic C3_6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl . hi particular, it includes methyl, 1- propenyl and l,2,3-triazol-5-yl tl iomethyl. The process comprising:
(i) . reacting a Dane salt of Formula III,
FORMULA III
wherein R' is C1-4 alkyl and M+is an alkali metal cation,
with a lower alkyl chloroformate in the presence of an amine, and an acid, to obtain a mixed carboxylic acid anhydride of Formula IN, and
HO— (( )) — CH— COOCOOAIkyl
I
ΝH I H3C— C=CHCOOR'
FORMULA IV
(ii) reacting the mixed carboxylic acid anhydride with a silylated derivative of the 7- amino-ceph-3-em-4-carboxylic acid of Formula II,
FORMULA II
wherein R is C1 6 alkyl, C,_6 alkenyl, C2_6 alkynyl, C2 6 alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl,
to obtain the cephem compound of Formula I.
hi general, the preparation of the mixed anhydride is carried out in the presence of a small amount of an acid to minimize the formation of impurity of Formula B, in the step ii) reaction,
FORMULA B
wherein R is a group commonly used at the 3-position in cephalosporins, and includes C. 6 alkyl, C2 6 alkenyl, C2 6 alkynyl, C2 6 alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl.
The process is useful for the preparation of a wide variety of 7- amino(p- hydroxyphenylglycyl) -cephalosporins, for example, cefatrizine, cefadroxil, or cefprozil, in good yield and purity.
Examples of Dane salts of Formula III include sodium or potassium D-N-(l- methoxycarbonylpropen-2-yl)amino-p-hydroxyphenyl- acetate, and sodium or potassium D-N-(l-ethoxycarbonyl- propen-2-yl)-amino-p-hydroxyphenylacetate.
Examples of alkyl chloro formates include ethyl chloroformate and methyl chloroformate.
Examples of amines present as a catalyst for mixed carboxylic acid anhydride formation include N-methyl morpholine, N,N-dimethyl benzyl amine, pyridine, picoline, and lutidine.
The mixed anhydride may be prepared in one or more solvents, including, for example, halogenated hydrocarbon, ketone, ester, ether, nitrile, aromatic hydrocarbon, amide and mixtures thereof. Examples of chlorinated hydrocarbons include dichoromethane and dichloroethylene; Examples of ketones include acetone and methyl isobutyl ketone; Examples of ester include ethyl acetate and isopropylacetate; Examples of ether include tetrahydrofuran and dioxane; a nitrile includes acetonitrile; Examples of aromatic hydrocarbon include toluene. A suitable co-solvent may be used with a solvent, for example amide. A suitable amide includes one or more of formamide, acetamide, N,N- dimethyl formamide, N-methylacetamide, N,N-dimethylacetamide and N- methylpyrrolidone. Mixtures of all of these solvents are also contemplated.
The formation of the mixed carboxylic acid anhydride may be carried out at temperatures, from about -80°C to about 50°C, or from about -50°C to about 5°C.
The product of step i) is generally obtained as a solution or a suspension of the mixed carboxylic acid anhydride, and can be further used as such. If desired, this anhydride may be maintained at from about -60°C to about -20°C.
The 7-amino-ceph-3-em-4-carboxylic acid of Formula II maybe silylated with silylation agents in a solvent inert under the reaction conditions. Examples of silylation agents include mono- or bissilylated amides, such as N,0-bis-(trimethylsilyl)acetamide (BSA), N-methyl-N-trimethylsilyl-acetamide (MSA); silylated ureas, such as N,N'-bis- (trimethylsilyl)-urea (BSU); or silazanes, such as 1 1 3,3,3- hexamethyldisilazane (HMDS), in combination with a halosilane such as trimethylchlorsilane, dimethyldichlorosilane, or an amine, such as triethylamine, tert.octylamine.
The solvents used for mixed anhydride preparation above may be used for silylation of the 7-amino-ceph-3-em-4-carboxylic acid, and also for the step ii) reaction.
The reaction temperatures for the step ii) may be from about -60°C to room temperature or from about -40 ° C to about -10°C.
The reaction mixture of the step ii) may be worked up in a conventional manner. The substituted vinyl group may be split by hydrolysis in aqueous acid.
The final product may be isolated in a conventional manner, for example by adjusting the pH of the reaction mixture. The product of Formula I can be obtained in a very high purity, for example above 98%.
The 7-amino-ceph-3-em-4-carboxylic acid of Formula II may be prepared in accordance with any of the known methods (see U.S. Patent Nos. 3,867,380; 3 489,752 and 4,520,022).
The Dane salt of Formula III may be obtained from commercial sources or prepared by methods well known in the art.
Thus, compounds of Formula I having less than 0.5% by weight of the impurity of Formula B can be obtained. In particular, compounds of Formula I having less than 0.1% by weight of the impurity of Formula B, or less than 0.05% can be obtained.
The resulting cephem compounds of Formula I may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. hi these cases, the medicaments can be prepared by conventional methods with conventional pharmaceutical excipients.
The compositions include dosage forms suitable for oral and parenteral (including subcutaneous, intramuscular, and ophthalmic) administration. The oral dosage forms may include solid dosage forms, like powder, tablets, capsules, as well as liquid suspensions. Parenteral dosage forms may include intravenous infusions, sterile solutions for intramuscular, subcutaneous or intravenous administration, dry powders to be reconstituted with sterile water for parenteral administration, and the like.
The present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and are not intended to limit the scope of the invention. Although the examples are directed to the cefprozil and cefdroxil, the principles described in these examples can be applied to other cephem compounds.
Example 1
Cefprozil
7-amino-3-(propen-l-yl)-3-cephem-4-carboxylic acid (7-APCA, 50g) was added to methylene chloride (300ml). 1,1,3,3-hexamethylsilazane (25g), chlorotrimethylsilane (17.5g) and imidazole (0.5g) were added. The reaction mixture was refluxed for 3-4 hours and then cooled to 0 to 5°C.
Potassium (D)-N-(l-methyoxycarbonyl-propen-2-yl)-o;-ammo-p-hydroxyphenyl acetate (Dane salt, 71g) was added to methylene chloride (300ml) and dimethylformamide (200ml) and stirred at -40 to -45°C. N-methylmorpholine (0.42g) and methanesulfonic acid (1.0 g) were added followed by ethylchloroformate (28.2g) and stirred for about 90 minutes at -35 to -40°C. It was then cooled to -65 to -70°C.
The suspension of silylated 7-APCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes. A mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C. The aqueous layer was diluted with dimethylformamide(700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution. The mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered. The solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 98g of cefprozil as dimethyl formamide (1.5 mole) solvate.
Moisture content by KF = 0.25%; HPLC purity =99.58%; DMF content (by GC) = 18.2%
Impurity of formula B (R = 1-propenyl, Alkyl = ethyl) = 0.05% (by HPLC)
Above cefprozil dimethyl formamide solvate was converted to crystalline cefprozil monohydrate by the procedure reported in U.S. Patent No. 4,694,079.
Example 2
Cefadroxil
7-amino-3-desacetoxy-3-cephem-4-carboxylic acid (7-ADCA, 50g) was added to methylene chloride (300ml). 1,1,3,3-hexamethylsilazane (26g), chlorotrimethylsilane (18.7g) and imidazole (0.5g) were added. The reaction mixture was refluxed for 3-4 hours and then cooled to 0 to 5°C.
Potassium (D)-N-( 1 -methyoxycarbonyl-propen-2-yl)-α-amino-p-hydiOxyphenyl acetate (Dane salt, 79g) was added to methylene chloride (300ml) and dimethylformamide (200ml) and stirred at -40 to -45°C. N-methylmorpholine (0.47g) and methanesulfonic acid (1.12 g) were added followed by ethylchloroformate (29.5g) and stirred for about 90 minutes at -35 to -40°C. It was then cooled to -65 to -70°C.
The suspension of silylated 7-ADCA was added to the above mixed anhydride at - 65 to - 70°C and further stirred for 60 minutes at -40 to -45°C. The temperature was raised to -20 to -25°C and further stirred for 90 minutes. A mixture of water (170ml) and 35% hydrochloric acid (35 ml) was added to the reaction mixture and stirred for 15 minutes at 0 to 5°C. The aqueous layer was diluted with dimethylformamide (700ml) and acetone (150 ml), and pH of the mixture adjusted to 6.5 with 25% ammonia solution. The mixture was stirred at 20-25°C for 2 hours and the separated solid was filtered. The solvate was washed dimethylformamide (100 ml) followed by acetone and dried at 40°C to yield 105g of cefadroxil as dimethyl formamide (1.5 mole) solvate.
Moisture content by KF = 0.48%; HPLC purity =99.24%; DMF content (by GC) = 22.8%
Impurity of formula B (R = methyl, Alkyl = ethyl) = 0.08% (by HPLC)
Above cefadroxil dimethyl formamide solvate was converted to white crystalline solid cefadroxil monohydrate by the procedure reported in U.S. Patent No. 4,504,657.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Claims
1. A process for the production of a cephem compound of Formula I,
FORMULA I
wherein R is C1 6 alkyl, C2_6 alkenyl, C2_6 allcynyl, C2 g alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl, the process comprising:
i) reacting a Dane salt of Formula III,
FORMULA III
wherein R' is Cχ 4 alkyl and M+ is an alkali metal cation, with a lower alkyl chloroformate in the presence of an amine, and an acid, to obtain a mixed carboxylic acid anhydride of Formula IN,
FORMULA IN
wherein R' is as defined above and alkyl is methyl or ethyl, and
ii) reacting the mixed carboxylic acid anhydride with a silylated derivative of the 7-amino-ceph-3-em-4-carboxylic acid of Formula II, FORMULA E
wherein R is as defined above,
to obtain the cephem compound of Formula I. 2. The process of claim 1, wherein the R group is methyl, 1-propenyl and 1,
2,3- triazol-5-yl thiomethyl.
3. The process of claim 1, wherein the Dane salt used in step i) is selected from the group consisting of sodium or potassium D-N-( 1 -methoxycarbonylpropen-2-yl)ammo-p- hydroxyphenyl- acetate, and sodium or potassium D-N-(l-ethoxycarbonyl- propen-2-yl)- amino-p-hydroxyphenylacetate.
4. The process of claim 1, wherein the alkyl chloro formates is ethyl chloroformate or methyl chloroformate.
5. The process of claim 1, wherein the amine is selected from the group consisting of N-methyl morpholine, N,N-dimethyl benzyl amine, pyridine, picoline, and lutidine.
6. The process of claim 1, wherein step i) is performed in a solvent.
7. The process of claim 6, wherein the solvent comprises one or more of a halogenated hydrocarbon, ketone, ester, ether, nitrile, aromatic hydrocarbon or mixtures thereof.
8. The process of claim 7, wherein the solvent is selected from the group consisting of dichloromethane, dichloroethylene, acetone, methyl isobutyl ketone, ethyl acetate, isopropylacetate, tetrahydrofuran, dioxane, acetonitrile and toluene.
9. The process of claim 1, wherein the step i) is carried out at temperature from about -80°C to about 50°C.
10. The process of claim 9, wherein the step i) is carried out at temperature from about -50°C to about 5°C.
11. The process of claim 6, wherein a co-solvent is used.
12. The process of claim 11, wherein the co-solvent is selected from the group consisting of formamide, acetamide, N,N-dimethyl formamide, N-methylacetamide, N,N- dimethylacetamide, and N-methylpyrrolidone.
13. The process of claim 1, wherein the step ii) is performed in a solvent.
14. The process of claim 13, wherein the solvent comprises one or more of halogenated hydrocarbon, ketone, ester, ether, nitrile, aromatic hydrocarbon, or mixtures thereof.
15. The process of claim 14, wherein the solvent is selected from the group consisting of dichloromethane, dichloroethylene, acetone, methyl isobutyl ketone, ethyl acetate, isopropylacetate, tetrahydrofuran, dioxane, acetonitrile and toluene.
16. The process of claim 1, wherein the step ii) is carried out at temperatures from about -60°C to about 25°C.
17. The process of claim 16, wherein the step ii) is carried out at temperatures from about -40°C to about - 10°C.
18. The process of claim 1, wherein the silylation of the 7-amino-ceph-3-em-4- carboxylic acid of Formula II is carried out with a silylation agent selected from the group consisting of mono- or bissilylated amides, silylated ureas, and silazanes, in combination with a halosilane or an amine.
19. The process of claim 18, wherein the silylation agent is selected from the group consisting of N,0-bis-(trimethylsilyl)acetamide (BSA), N-methyl-N-trimethylsilyl- acetamide (MSA), N,N'-bis-(trimethylsilyl)-urea (BSU), and 1 1 3,3,3- hexamethyldisilazane (HMDS),
20. The process of claim 18, wherein the halosilane is trimethylchlorsilane and dimethyldichlorosilane.
21. The process of claim 18, wherein the amine comprises one or more of triethylamine, and tert.octylamine.
22. Compounds of Formula I,
FORMULA I
wherein R is Cl g alkyl, C2 g alkenyl, C2 6 alkynyl, C2 6 alkadienyl, cyclic C3 6 alkyl, aryl, substituted aryl, heteroaryl, or heteroarylthioalkyl,, having less than 0.5% by weight of the impurity of Formula B,
FORMULA B
wherein R is as defined above.
23. The compound of claim 22, wherein the R group is methyl, 1-propenyl and 1,2,3- triazol-5-yl thiomethyl.
24. The compound of claim 22, wherein the impurity of Formula B is less than 0.1 % by weight.
25. The compound of claim 24, wherein the impurity of Formula B is less than 0.05% by weight.
26. The compound of claim 22 or 23, wherein the alkyl group in the impurity of Formula B is methyl or ethyl.
27. A pharmaceutical composition comprising the compound of claim 22 or 23 optionally together with pharmaceutically acceptable carriers, excipients or diluents.
28. A pharmaceutically acceptable composition comprising a pharmaceutically acceptable effective amount of a compound according to claim 22 or 23 with a pharmaceutically acceptable carrier for treating bacterial infections.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
INDE03532003 | 2003-03-21 | ||
IN353DE2003 | 2003-03-21 | ||
PCT/IB2004/000850 WO2004083172A2 (en) | 2003-03-21 | 2004-03-22 | Process for the preparation of 7-amino (p-hydroxyphenylglyclyamido) cephem compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1608661A2 true EP1608661A2 (en) | 2005-12-28 |
Family
ID=33017825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04722335A Withdrawn EP1608661A2 (en) | 2003-03-21 | 2004-03-22 | Process for the preparaton of 7-(p-hydroxyphenylglycylamido)cephem compounds |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1608661A2 (en) |
CA (1) | CA2519853A1 (en) |
WO (1) | WO2004083172A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1809638T3 (en) * | 2004-11-01 | 2010-07-30 | Hetero Drugs Ltd | A novel process for preparation of cefprozil intermediate |
CN102408438B (en) * | 2010-09-26 | 2015-01-07 | 石药集团中奇制药技术(石家庄)有限公司 | Preparation method of cefprozil monohydrate |
CN102443013B (en) * | 2010-10-10 | 2014-09-17 | 石药集团中奇制药技术(石家庄)有限公司 | Method for preparing cefprozil dimethyl formamide solvate |
CN102911187B (en) * | 2012-10-11 | 2015-03-11 | 南通康鑫药业有限公司 | Recovery method of cefprozil |
CN112694487B (en) * | 2020-12-29 | 2022-04-22 | 苏州盛达药业有限公司 | Preparation method of cefprozil |
CN113533591B (en) * | 2021-06-18 | 2022-08-23 | 山东罗欣药业集团恒欣药业有限公司 | GC analysis method for benzene and paraldehyde in cefprozil |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899394A (en) * | 1972-12-26 | 1975-08-12 | Bristol Myers Co | Production of antibacterial agents |
FR2215939B1 (en) * | 1973-01-31 | 1976-07-02 | Roussel Uclaf | |
GB1505345A (en) * | 1974-04-10 | 1978-03-30 | Beecham Group Ltd | Cephalosporins |
US4148817A (en) * | 1976-03-25 | 1979-04-10 | Eli Lilly And Company | Process and intermediates for preparing cephalosporin antibiotics |
IT1065387B (en) * | 1976-12-16 | 1985-02-25 | Dobfar Spa | PROCEDURE FOR THE PREPARATION OF CEPHALOSPORINE |
KR820001564B1 (en) * | 1981-05-09 | 1982-09-02 | 동신제약 주식회사 | Process for preparing cephalosporin derivatives |
US20040077849A1 (en) * | 2002-10-16 | 2004-04-22 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of cefadroxil |
US6903211B2 (en) * | 2002-10-30 | 2005-06-07 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of 3-propenyl cephalosporin DMF solvate |
-
2004
- 2004-03-22 CA CA002519853A patent/CA2519853A1/en not_active Abandoned
- 2004-03-22 WO PCT/IB2004/000850 patent/WO2004083172A2/en not_active Application Discontinuation
- 2004-03-22 EP EP04722335A patent/EP1608661A2/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2004083172A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004083172A3 (en) | 2004-12-02 |
CA2519853A1 (en) | 2004-09-30 |
WO2004083172A2 (en) | 2004-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6552186B2 (en) | β-lactam production | |
US7427692B2 (en) | Process for preparation of 7-[α-amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid | |
EP0233271B1 (en) | Process for preparing cephalosporin intermediates | |
US5461043A (en) | Diastereomers of 1-(isopropoxycarbonyloxy)ethyl 3-cephem-4-carboxylate | |
EP1068211B1 (en) | Process for purification of a cephalosporin derivative | |
EP1608661A2 (en) | Process for the preparaton of 7-(p-hydroxyphenylglycylamido)cephem compounds | |
WO2002083634A2 (en) | Process for the preparation of cefpodoxime acid | |
WO2006008749A1 (en) | Process for preparing pure cephalosporine intermediates | |
US5998610A (en) | Silylation process | |
CZ282160B6 (en) | Process for preparing cephepimdihydrochloride hydrate antibiotic and intermediate for preparing thereof | |
RO109652B1 (en) | Hydrate dihydrochloride cefepim antibiotic preparation process | |
EP1809638B1 (en) | A novel process for preparation of cefprozil intermediate | |
US4868294A (en) | Process for preparing cephalosporin intermediates | |
KR920001769B1 (en) | A process for preparing chlorocefadroxil monohydrate | |
JP4616844B2 (en) | Production process of intermediates for use in the synthesis of cephalosporin | |
KR840002046B1 (en) | Process for preparing cepharosporins | |
WO2005040175A2 (en) | Process for the preparation of cephem carboxylic acids | |
US20040077849A1 (en) | Process for the preparation of cefadroxil | |
WO2002004463A1 (en) | Novel cephalosporin compounds and process for preparing the same | |
AU2002307885A1 (en) | Process for the preparation of cefpodoxime acid | |
JP2005521692A (en) | Novel cephalosporin compound and method for producing the same | |
MXPA96005773A (en) | Cephalosporine compounds and processes for the preparation of mis | |
JPH0322391B2 (en) | ||
JPS6117837B2 (en) | ||
JPH10182656A (en) | Cephem compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051021 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071002 |